Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kong, Dejuan ^a   Heath, Elisabeth ^a   Chen, Wei ^a   Cher, Michael L ^a   Powell, Isaac ^a   Heilbrun, Lance ^a   Li, Yiwei ^a   Ali, Shadan ^a   Sethi, Seema ^a   Hassan, Oudai ^a   Hwang, Clara ^b   Gupta, Nilesh ^b   Chitale, Dhananjay ^b   Sakr, Wael A ^a   Menon, Mani ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; ONCOPROTEIN; PROTEIN LET 7; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 1,1 BIS(3' INDOLYL)METHANE; 1,1-BIS(3'-INDOLYL)METHANE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; INDOLE DERIVATIVE; MICRORNA; MIRNLET7 MICRORNA, HUMAN; RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; ATTENUATION; CANCER STEM CELL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE LOSS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROSTATECTOMY; UPREGULATION; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RNA, NEOPLASM; TRANSCRIPTION FACTORS;

EID: 84863343713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033729     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Sumey C, Flaig TW, (2011) Adjuvant medical therapy for prostate cancer. Expert Opin Pharmacother 12: 73-84.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597.
5. Kattan MW, Wheeler TM, Scardino PT, (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499-1507.
6. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
7. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL, (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923.
8. Peter ME, (2009) Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8: 843-852.
9. Sarkar FH, Li Y, Wang Z, Kong D, Ali S, (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13: 57-66.
10. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, et al. (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105: 3903-3908.
11. Mayr C, Hemann MT, Bartel DP, (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579.
12. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, et al. (2009) HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev 23: 1743-1748.
13. Barh D, Malhotra R, Ravi B, Sindhurani P, (2010) MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17: 70-80.
14. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, et al. (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16: 430-441.
15. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, et al. (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745.
16. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, et al. (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6: e18064.
17. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
18. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5: e12445.
19. Viswanathan SR, Daley GQ, Gregory RI, (2008) Selective blockade of microRNA processing by Lin28. Science 320: 97-100.
20. Yang X, Lin X, Zhong X, Kaur S, Li N, et al. (2010) Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 70: 9463-9472.
21. Zhong X, Li N, Liang S, Huang Q, Coukos G, et al. (2010) Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 285: 41961-41971.
22. Ji J, Wang XW, (2010) A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis. J Hepatol 53: 974-975.
23. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, et al. (2011) LIN28B promotes colon cancer progression and metastasis. Cancer Res 71: 4260-4268.
24. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, et al. (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349-353.
25. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
26. Bracken AP, Helin K, (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9: 773-784.
27. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
28. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284.
29. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, et al. (2008) Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 28: 4772-4781.
30. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874.
31. Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, et al. (2010) A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res 2: 402-411.
32. Sarkar FH, Li Y, (2004) Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 555: 53-64.
33. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 Regulates PDGF-D-Mediated Epithelial-Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells. Stem Cells 27: 1712-1721.
34. Ustach CV, Kim HR, (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25: 6279-6288.
35. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH, (2007) Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67: 3310-3319.
36. Benjamini Y, Krieger AM, Yekutieli D, (2006) Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93: 491-507.
37. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699.
38. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, et al. (2010) Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 16: 5414-5423.
39. Simon JA, Lange CA, (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29.
40. Fujii S, Ochiai A, (2008) Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99: 738-746.
41. Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, et al. (2001) Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 166: 705-709.
42. Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, et al. (2007) Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 6: 391-403.
43. Tryndyak VP, Beland FA, Pogribny IP, (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126: 2575-2583.
44. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, et al. (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128: 1327-1334.
45. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, et al. (2011) Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell 20: 187-199.
46. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 Regulates PDGF-D-Mediated Epithelial-Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells. Stem Cells 27: 1712-1721.
47. Kong D, Li Y, Wang Z, Sarkar FH, (2011) Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 3: 716-729.
48. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, et al. (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495.
49. Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, et al. (2004) Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 10: 5233-5241.
50. Anderton MJ, Jukes R, Lamb JH, Manson MM, Gescher A, et al. (2003) Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 787: 281-291.